Live tape
Top 8, mentions 7d10,808GOOGL2,066 mentions▲ +0.04SNDK1,527 mentions▲ +0.11SPCX1,496 mentions▲ +0.08NBIS1,423 mentions▲ +0.10HTZ1,232 mentions▲ +0.10NVDA1,196 mentions▲ +0.08META1,026 mentions▲ +0.03MSFT842 mentions▲ +0.06

Equity · Healthcare

FDMT

4D Molecular Therapeutics, Inc. · NasdaqGS

$10.98 −0.18% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart
Our own end-of-day closes 40 sessions
$14 $8 20 May 17 Jul

The line runs $8.48 on 20 May through $10.98 on 17 July, on a scale from $8 to $14. Days the market did not trade hold the previous close, flat.

The chart above plots the price of FDMT over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 40 sessions over that window: $8.48 on 20 May 2026 through $10.98 on 17 July 2026.

Market cap $759.5M
52-week range $4.16 – $13.32
Avg volume 193.5K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 18, 2026

FDMT insider trades

SEC Form 4

FDMT has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 12 December 2025.

Date Insider Type Shares Value
17 Nov 2025 Bizily Scott Chief Legal Officer Sell 1,635 $17K
24 Oct 2025 Bizily Scott Chief Legal Officer Sell 2,678 $32K
16 Oct 2025 Bizily Scott Chief Legal Officer Sell 1,635 $17K
09 Oct 2025 Bizily Scott Chief Legal Officer Sell 2,408 $24K
23 Sep 2025 Bizily Scott Chief Legal Officer Sell 2,407 $19K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
12 Dec 2025 THEUER CHARLES Option exercise 9,333 $11K
09 Dec 2025 Humer Kristian Chief Financial Officer Award 480,000
17 Nov 2025 Bizily Scott Chief Legal Officer Option exercise 1,635 $7K
24 Oct 2025 Bizily Scott Chief Legal Officer Option exercise 1,084 $7K
16 Oct 2025 Bizily Scott Chief Legal Officer Option exercise 1,635 $7K

FDMT reported financials

SEC EDGAR XBRL

FDMT reported revenue of $85.2M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$140.1M.

Figure Reported Period
Revenue $85.2M 31 Dec 2025 fiscal year
Net income −$140.1M 31 Dec 2025 fiscal year
Diluted EPS −$2.42 31 Dec 2025 fiscal year
Total assets $492.6M 30 Jun 2026 at period end
Total equity $407.7M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

FDMT earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-1.04 $4M
31 Mar 2026 Q1 2026 $-1.01 $3M
31 Dec 2025 FY 2025 $-2.42 $85M
30 Sep 2025 Q3 2025 $-1.01
30 Jun 2025 Q2 2025 $-0.98 $0M
31 Mar 2025 Q1 2025 $-0.86 $0M
31 Dec 2024 FY 2024 $-2.98 $0M
30 Sep 2024 Q3 2024 $-0.79 $0M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

FDMT institutional holders

SEC Form 13F

8 of the 45 institutional funds we track reported a FDMT position for the quarter ended 30 Jun 2026 — a combined $21.6M; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Citadel Advisors Added +160.4% shares 687,597 $9.1M
Renaissance Technologies Held (±25%) +6.3% shares 614,573 $8.2M
Two Sigma Investments Trimmed −44.1% shares 69,481 $924K
Man Group Added +135.8% shares 68,349 $909K
Fisher Asset Management New position 65,751 $874K
AQR Capital Management Held (±25%) +9.8% shares 50,281 $669K
D. E. Shaw & Co. Added +84.6% shares 44,354 $590K
Marshall Wace Added +27.6% shares 21,342 $284K

Source: SEC EDGAR 13F filings

FDMT fails-to-deliver

SEC CNS data

On 31 Jul 2026, 1,503 shares of FDMT failed to deliver (about $15K).

Settlement date Shares failed Notional % of shares out
31 Jul 2026 1,503 $15K 0.002%
23 Jul 2026 1,381 $15K 0.002%
22 Jul 2026 136 $2K <0.001%
20 Jul 2026 9,797 $108K 0.014%
17 Jul 2026 1,390 $15K 0.002%
16 Jul 2026 40 $467 <0.001%

Source: SEC fails-to-deliver (CNS) data